Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | aminoadipate aminotransferase | Starlite/ChEMBL | References |
Rattus norvegicus | Kynurenine/alpha-aminoadipate aminotransferase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Neospora caninum | aminotransferase, putative | Get druggable targets OG5_127007 | All targets in OG5_127007 |
Candida albicans | Aromatic amino acid aminotransferase I | Get druggable targets OG5_127007 | All targets in OG5_127007 |
Candida albicans | Aromatic amino acid aminotransferase I | Get druggable targets OG5_127007 | All targets in OG5_127007 |
Candida albicans | similar to S. cerevisiae YER152C | Get druggable targets OG5_127007 | All targets in OG5_127007 |
Toxoplasma gondii | aminotransferase, putative | Get druggable targets OG5_127007 | All targets in OG5_127007 |
Candida albicans | similar to S. cerevisiae YER152C | Get druggable targets OG5_127007 | All targets in OG5_127007 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | glutamine aminotransferase (GlnAT) | Kynurenine/alpha-aminoadipate aminotransferase | 425 aa | 359 aa | 22.6 % |
Candida albicans | similar to aromatic amino acid aminotransferase II | Kynurenine/alpha-aminoadipate aminotransferase | 425 aa | 379 aa | 30.1 % |
Candida albicans | Aromatic amino acid aminotransferase | Kynurenine/alpha-aminoadipate aminotransferase | 425 aa | 379 aa | 30.1 % |
Mycobacterium ulcerans | transcriptional regulator | Kynurenine/alpha-aminoadipate aminotransferase | 425 aa | 342 aa | 21.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0945 | 1 | 0.5 | |
Brugia malayi | Hypothetical tyrosinase-like protein F21C3.2 in chromosome I | 0.0945 | 1 | 0.5 |
Brugia malayi | Common central domain of tyrosinase family protein | 0.0945 | 1 | 0.5 |
Brugia malayi | Hypothetical tyrosinase-like protein C02C2.1 in chromosome III | 0.0945 | 1 | 0.5 |
Schistosoma mansoni | tyrosinase precursor | 0.0945 | 1 | 0.5 |
Loa Loa (eye worm) | tyrosinase 1 | 0.0945 | 1 | 0.5 |
Loa Loa (eye worm) | ShTK domain-containing protein | 0.0945 | 1 | 0.5 |
Toxoplasma gondii | aminotransferase, putative | 0.0427 | 0 | 0.5 |
Onchocerca volvulus | 0.0945 | 1 | 0.5 | |
Brugia malayi | Hypothetical tyrosinase-like protein C02C2.1 in chromosome III | 0.0945 | 1 | 0.5 |
Loa Loa (eye worm) | ShTK domain-containing protein | 0.0945 | 1 | 0.5 |
Brugia malayi | Hypothetical tyrosinase-like protein C02C2.1 in chromosome III | 0.0945 | 1 | 0.5 |
Schistosoma mansoni | tyrosinase precursor | 0.0945 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0945 | 1 | 0.5 |
Onchocerca volvulus | 0.0945 | 1 | 0.5 | |
Onchocerca volvulus | 0.0945 | 1 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0945 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 572 nM | Inhibition of human recombinant KAT2 assessed as conversion of L-kynurenine into kynurenic acid after 15 to 20 hrs | ChEMBL. | 24900455 |
IC50 (binding) | > 10000 nM | Inhibition of rat recombinant KAT2 assessed as conversion of L-kynurenine into kynurenic acid after 15 to 20 hrs | ChEMBL. | 24900455 |
Ratio (binding) | = 21.3 /M/s | Ratio of Kinact to Ki for human recombinant KAT2 using L-kynurenine as substrate | ChEMBL. | 24900455 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.